A prospective study of plasma lipid levels and hypertension in women

Archives of Internal Medicine

Volumn 165, Issue 20, 2005, Pages 2420-2427

  Sesso, Howard D ^a,b   Buring, Julie E ^a,b,c   Chown, Marilyn J ^a   Ridker, Paul M ^a   Gaziano, J Michael ^a,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANAMNESIS; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HEALTH PRACTITIONER; HUMAN; HYPERTENSION; INFORMATION PROCESSING; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

BODY MASS INDEX; C-REACTIVE PROTEIN; COMORBIDITY; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; LIPIDS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK; RISK FACTORS; UNITED STATES;

EID: 27844518270     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.165.20.2420     Document Type: Article

References (44)

1. Kannel WB, Sorlie P. Hypertension in Framingham. In: Paul O, ed. Epidemiology and Control of Hypertension. Miami, Fla: Symposia Specialists; 1975:553-592.
2. Afonso LC, Edelson GW, Sowers JR. Metabolic abnormalities in hypertension. Curr Opin Nephrol Hypertens. 1997;6:219-223.
3. Gaziano JM, Sesso HD, Breslow JL, Hennekens CH, Buring JE. Relation between systemic hypertension and blood lipids on the risk of myocardial infarction. Am J Cardiol. 1999;84:768-773.
4. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med. 2003;139:761-776.
5. Rubba P, Mancini M. Lipid-lowering treatment: effects on endothelial dysfunction. Curr Opin Lipidol. 1995;6:348-353.
6. Kool M, Lustermans F, Kragten H, et al. Does lowering of cholesterol levels influence functional properties of large arteries? Eur J Clin Pharmacol. 1995;48:217-223.
7. Pearson TA, Swan HJ. Lipid lowering: the case for identifying and treating the high-risk patient. Cardiol Clin. 1996;14:117-130.
8. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest. 1993;92:652-662.
9. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 1989;2:997-1000.
10. Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14:2084-2091.
11. Reaven GM. Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension: parallels between human disease and rodent models. Diabetes Care. 1991;14:195-202.
12. Zavaroni I, Mazza S, Dall'Aglio E, Gasparini P, Passeri M, Reaven GM. Prevalence of hyperinsulinemia in patients with high blood pressure. J Intern Med. 1992;231:235-240.
13. Haffner SM, Ferrannini E, Hazuda HP, Stern MP. Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension. 1992;20:38-45.
14. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Metabolic precursors of hypertension: the San Antonio Heart Study. Arch Intern Med. 1996;156:1994-2000.
15. Hunt SC, Stephenson SH, Hopkins PN, Williams RR. Predictors of an increased risk of future hypertension in Utah: a screening analysis. Hypertension. 1991;17:969-976.
16. Skarfors ET, Lithell HO, Selinus I. Risk factors for the development of hypertension: a 10-year longitudinal study in middle-aged men. J Hypertens. 1991;9:217-223.
17. Borghi C, Veronesi M, Bacchelli S, Esposti DD, Cosentino E, Ambrosioni E. Serum cholesterol levels, blood pressure response to stress and incidence of stable hypertension in young subjects with high normal blood pressure. J Hypertens. 2004;22:265-272.
18. Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JE. Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med. 2000;9:19-27.
19. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304.
20. Klag MJ, He J, Mead LA, Ford DE, Pearson TA, Levine DM. Validity of physicians' self-reports of cardiovascular disease risk factors. Ann Epidemiol. 1993;3:442-447.
21. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290:2945-2951.
22. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
23. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report [published correction appears in JAMA. 2003;290:197]. JAMA. 2003;289:2560-2571.
24. Selby JV, Newman B, Quiroga J, Christian JC, Austin MA, Fabsitz RR. Concordance for dyslipidemic hypertension in male twins. JAMA. 1991;265:2079-2084.
25. Castelli WP, Anderson K. A population at risk: prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Med. 1986;80:23-32.
26. Haffner SM, Fong D, Hazuda HP, Pugh JA, Patterson JK. Hyperinsulinemia, upper body adiposity and cardiovascular risk factors in nondiabetics. Metabolism. 1988;37:338-345.
27. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275:1571-1576.
28. Williams RR, Hunt SC, Hopkins PN, et al. Familial dyslipidemic hypertension: evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA. 1988;259:3579-3586.
29. Hunt SC, Wu LL, Hopkins PN, et al. Apolipoprotein, low density lipoprotein subfraction, and insulin associations with familial combined hyperlipidemia: study of Utah patients with familial dyslipidemic hypertension. Arteriosclerosis. 1989;9:335-344.
30. Mundal R, Kjeldsen SE, Sandvik L, Erikssen G, Thaulow E, Erikssen J. Clustering of coronary risk factors with increasing blood pressure at rest and during exercise. J Hypertens. 1998;16:19-22.
31. Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol. 2002;39:1020-1025.
32. Selwyn AP, Kinlay S, Libby P, Ganz P. Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease. Circulation. 1997;95:5-7.
33. Nohria A, Garrett L, Johnson W, Kinlay S, Ganz P, Creager MA. Endothelin-1 and vascular tone in subjects with atherogenic risk factors. Hypertension. 2003;42:43-48.
34. Mangiafico RA, Malatino LS, Santonocito M, Spada RS, Polizzi G, Tamburino G. Raised plasma endothelin-1 concentrations in patients with primary hypercholesterolemia without evidence of atherosclerosis. Int Angiol. 1996;15:240-244.
35. Parissis JT, Venetsanou KF, Mentzikof DG, et al. Plasma levels of soluble cellular adhesion molecules in patients with arterial hypertension: correlations with plasma endothelin-1. Eur J Intern Med. 2001;12:350-356.
36. Parissis JT, Korovesis S, Giazitzoglou E, Kalivas P, Katritsis D. Plasma profiles of peripheral monocyte-related inflammatory markers in patients with arterial hypertension: correlations with plasma endothelin-1. Int J Cardiol. 2002;83:13-21.
37. Hirai Y, Adachi H, Fujiura Y, Hiratsuka A, Enomoto M, Imaizumi T. Plasma endothelin-1 level is related to renal function and smoking status but not to blood pressure: an epidemiological study. J Hypertens. 2004;22:713-718.
38. Alexander RW. Theodore Cooper Memorial Lecture: hypertension and the pathogenesis of atherosclerosis. Hypertension. 1995;25:155-161.
39. Chobanian AV, Alexander RW. Exacerbation of atherosclerosis by hypertension: potential mechanisms and clinical implications. Arch Intern Med. 1996;156:1952-1956.
40. Clarke R, Shipley M, Lewington S, et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies.AmJ Epidemiol. 1999;150:341-353.
41. Shih WJ, Bachorik PS, Haga JA, Myers GL, Stein EA. Estimating the long-term effects of storage at -70° C on cholesterol, triglyceride, and HDL-cholesterol measurements in stored sera. Clin Chem. 2000;46:351-364.
42. Giles WH, Croft JB, Keenan NL, Lane MJ, Wheller FC. The validity of self-reported hypertension and correlates of hypertension awareness among blacks and whites within the Stroke Belt. Am J Prev Med. 1995;11:163-169.
43. Colditz GA, Martin P, Stampfer MJ, et al. Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol. 1986;123:894-900.
44. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199-206.